Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders. In September 2008, the Company entered into a lease for laboratory space for a small scale research facility in San Diego, Calif. This facility will complement Amicus' core research and development activities in New Jersey, while allowing closer access to the significant scientific and biotechnology resources in the San Diego community.

Shire Collaboration:

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration, valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire reimburses world-wide development costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended September 30, 2008, was $8.2 million as compared to $10.3 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended September 30, 2008, was $6.6 million as compared to $9.2 million in the same period in 2007.

Amicus recorded revenue during the third quarter of 20
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... (PRWEB) July 24, 2014 Draper ... , is proud to announce that for 6 ... different countries will converge on the Draper University ... an intensive, experiential program focused on entrepreneurship, building ... selective school, currently running its sixth cohort, continues ...
(Date:7/24/2014)... As part of the long-term strategic ... MENA region during 2014 with potential global expansion. , ... with DZS to manage our clinical trials globally and ... of R&D and President of SBI pharmaceuticals MENA, Dr. ... with a focus on utilizing eClinical software and flexible ...
(Date:7/23/2014)... Emirates (UAE) (PRWEB) July 23, 2014 ... recently announced that its biobanking project, Provia ... Ph.D. to its growing Advisory Board. Scott Wolf ... pleased to have Dr. Vaught onboard with Provia’s ever-expanding ... and expertise that Provia’s management team brings to this ...
(Date:7/23/2014)... Physicists Sergei Filippov (MIPT and Russian Quantum Center ... Brno, Czech Republic, and the Institute of Physics ... preserve quantum entanglement of particles passing through an ... long distances. Details are provided in an article ... (see preprint). , Quantum entangled particles are ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4
... About 18 months ago, I sat with the product managers at ... were the $99 devices intended to be an entry-level digital organizer ... Shack and Target and wanted a simple product that delivered real ... a quick test drive, I leaned close to the product marketing ...
... Middleton, Wis. Standard Imaging , a Middleton-based ... treatment for cancer cardiology and other applications, has announced ... the assets acquired from the British Columbia-based company are ... with most electronic portal imaging devices (EPIDs). The PIPSpro ...
... The Wisconsin Alumni Research Foundation is suing ... computer memory chips, for allegedly using a patented technology developed ... in their semiconductors. , ,According to Andy Cohn, spokesman for ... is the same as previous legal actions against Sony ...
Cached Biology Technology:The Palm to "de-Zire" 2The Palm to "de-Zire" 3Standard Imaging acquires Canadian PIPSpro radiation treatment technologies 2WARF sues Samsung over computer chip technology license agreement 2
(Date:7/23/2014)... July 24, 2014 Pfenex Inc. (NYSE MKT: PFNX) ... 8,333,333 shares of its common stock at a price to ... granted the underwriters a 30-day option to purchase up to ... offering price. The shares are expected to begin trading on ... "PFNX". William Blair & Company, L.L.C. ...
(Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today ... the University of Massachusetts Amherst School of Public ... three-year, $700,000 Science to Achieve Results (STAR) grant ... by Native subsistence hunters in subarctic North America ... exposure and to provide culturally-relevant recommendations for mitigation. ...
(Date:7/23/2014)... State University shows that urban "heat islands" are slowly ... factor is that researchers have found warmer temperatures increase ... insect a significant tree pest by 300 ... adult gloomy scales on urban trees. , "We,d been ... scale in cities, and now we know why," says ...
Breaking Biology News(10 mins):Pfenex Inc. Announces Pricing Of Initial Public Offering 2Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3Urban heat boosts some pest populations 200-fold, killing red maples 2Urban heat boosts some pest populations 200-fold, killing red maples 3
... lot of variables come into play when selecting a site ... as wildlife needs, species and vegetation uniqueness, and costs to ... of Illinois researchers found that society and the environment ... are closer to people because people are more willing to ...
... Chemists and biologists have successfully demonstrated that specially synthesized ... a move that, they say, is a proof of ... In June 2008, University of Oregon chemist Shih-Yuan ... Chemical Society his lab,s synthesis of boron-nitrogen compounds ...
... Michigan are reporting the development of a powerful new probe ... in aging and disease. The probe works like a GPS ... could lead to new insights into disease processes and identify ... is scheduled for the Sept. 18 issue of ACS ...
Cached Biology News:Research recommends compromise when choosing conservation site 2Research recommends compromise when choosing conservation site 3Research recommends compromise when choosing conservation site 4Boron-based compounds trick a biomedical protein 2
SHEEP ANTI ESCHERICHIA COLI...
Recombinant Rat Leptin, CF...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
... • Holds 0.1 mL - 25 mL pipets ... pipets. Also accommodates most standard square or round pipet ... Has four compartments, each 76 mm W x 76 ... x 11 3/8 ins.). Overall dimensions: 89 mm W ...
Biology Products: